Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Engelhardt

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Mycoses|March 24, 2018
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trialJohn R Perfect, Oliver A Cornely, Markus Heep, et al.
Mycoses|July 24, 2018
Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazoleJohan Maertens, Dominik Selleslag, Werner J Heinz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2014
A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumoniaSamir S Awad, Alejandro H Rodriguez, Yin-Ching Chuang, et al.
Archives of Toxicology|May 25, 2017
Mechanisms of hepatotoxicity associated with the monocyclic β-lactam antibiotic BAL30072Franziska Paech, Simon Messner, Jochen Spickermann, et al.
European Heart Journal|December 25, 2004
Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiographyRainer Hoffmann, Stephan von Bardeleben, Folkert ten Cate, et al.
Expert Opinion on Investigational Drugs|October 26, 2021
Derazantinib: an investigational drug for the treatment of cholangiocarcinomaStephan Braun, Paul McSheehy, Karine Litherland, et al.
Investigational New Drugs|September 1, 2019
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumorsMarkus Joerger, Anastasios Stathis, Yannis Metaxas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 8, 2020
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)J Scott Overcash, Charles Kim, Richard Keech, et al.
Clinical and Translational Science|June 8, 2018
Prediction of Safety Margin and Optimization of Dosing Protocol for a Novel Antibiotic using Quantitative Systems Pharmacology ModelingJeffrey L Woodhead, Franziska Paech, Martina Maurer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 13, 2016
Isavuconazole Treatment of Cryptococcosis and Dimorphic MycosesGeorge R Thompson, Adrian Rendon, Rodrigo Ribeiro Dos Santos, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Mycoses|March 24, 2018
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trialJohn R Perfect, Oliver A Cornely, Markus Heep, et al.
Mycoses|July 24, 2018
Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazoleJohan Maertens, Dominik Selleslag, Werner J Heinz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2014
A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumoniaSamir S Awad, Alejandro H Rodriguez, Yin-Ching Chuang, et al.
Archives of Toxicology|May 25, 2017
Mechanisms of hepatotoxicity associated with the monocyclic β-lactam antibiotic BAL30072Franziska Paech, Simon Messner, Jochen Spickermann, et al.
European Heart Journal|December 25, 2004
Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiographyRainer Hoffmann, Stephan von Bardeleben, Folkert ten Cate, et al.
Expert Opinion on Investigational Drugs|October 26, 2021
Derazantinib: an investigational drug for the treatment of cholangiocarcinomaStephan Braun, Paul McSheehy, Karine Litherland, et al.
Investigational New Drugs|September 1, 2019
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumorsMarkus Joerger, Anastasios Stathis, Yannis Metaxas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 8, 2020
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)J Scott Overcash, Charles Kim, Richard Keech, et al.
Clinical and Translational Science|June 8, 2018
Prediction of Safety Margin and Optimization of Dosing Protocol for a Novel Antibiotic using Quantitative Systems Pharmacology ModelingJeffrey L Woodhead, Franziska Paech, Martina Maurer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 13, 2016
Isavuconazole Treatment of Cryptococcosis and Dimorphic MycosesGeorge R Thompson, Adrian Rendon, Rodrigo Ribeiro Dos Santos, et al.
Pageof 5